AHCO
AdaptHealth Corp.
AHCO trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over AHCO overall, supported by stronger fundamentals and lower modeled downside.
AHCO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Under pressure |
AHCO's revenue, profitability, cash flow and balance sheet are all currently under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AHCO PE Valuation
AHCO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AHCO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect AHCO's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AHCO on the outlook, with more favorable earnings and revenue expectations.
AHCO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.97 | -630% |
| Q2 2026 | -$1.68 | -405% |
| Q1 2026 | -$0.59 | -202% |
| Q4 2025 | -$0.52 | -185% |
| Q3 2025 | $0.56 | +$2.21 |
| Q2 2025 | $0.55 | +$5.78 |
| Q1 2025 | $0.58 | +$5.85 |
| Q4 2024 | $0.61 | +$5.92 |
AHCO has swung to a loss: it lost $2.97 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AHCO on earnings quality, reporting a profit while its opponent remains loss making.
AHCO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $745.6M | -9.1% |
| Q2 2026 | $740.3M | -7.5% |
| Q1 2026 | $819.8M | +5.4% |
| Q4 2025 | $846.3M | -1.2% |
| Q3 2025 | $820.3M | +1.8% |
| Q2 2025 | $800.4M | -0.7% |
| Q1 2025 | $777.9M | -1.8% |
| Q4 2024 | $856.6M | -0.2% |
AHCO's revenue grew through 2022 and has held roughly level since: $746M last quarter, down 9.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -21% | -28 points |
| Q2 2026 | -19% | -29 points |
| Q1 2026 | 0.7% | -2.3 points |
| Q4 2025 | -8.7% | -20 points |
| Q3 2025 | 7.5% | -0.3 points |
| Q2 2025 | 9.9% | +3.4 points |
| Q1 2025 | 3% | -3.4 points |
| Q4 2024 | 11% | +37 points |
AHCO's operating margin was −21% last quarter, down 28 points from the same quarter a year ago, near the bottom of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AHCO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AHCO on profitability, with a higher operating margin.
AHCO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $51.1M | -24% |
| Q2 2026 | -$20.9M | -129% |
| Q1 2026 | -$27.5M | -$27.4M |
| Q4 2025 | $79.3M | +8.5% |
| Q3 2025 | $66.8M | -21% |
| Q2 2025 | $73.3M | -37% |
| Q1 2025 | -$58K | +$38.8M |
| Q4 2024 | $73.1M | +9.7% |
AHCO still generates free cash flow, though less than at its 2024 peak: $82M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AHCO on cash flow, with more consistent year-over-year improvement.
AHCO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +276K shares |
| 1 year | -0.6% | -815K shares |
| 3 years | +1% | +1.4M shares |
| 5 years | -2.8% | -3.9M shares |
| Available history | +225% | +94.4M shares |
AHCO has 136M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $20.1M |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $9.2M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AHCO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 3.8x | Elevated |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 3.2x | Elevated |
| Q4 2024 | 3.0x | Moderate |
| Q3 2024 | 6.1x | High |
| Q3 2023 | 54.3x | High |
AHCO's net debt is about 3.8 years of its operating earnings (EBITDA), up from 3.2 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AHCO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.5 | Neutral |
| Stochastic | 47.7 | Neutral |
AHCO's weekly RSI is 51 (neutral) and its Stochastic is 48 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AHCO PE vs Healthcare Sector
| Metric | AHCO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AHCO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AHCO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.29 | 25% above |
| 20 week MA | $7.25 | 8.6% above |
| 50 week MA | $9.26 | 15% below |
| 100 week MA | $9.31 | 15% below |
| 200 week MA | $10.1 | 22% below |
AHCO has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 22% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AHCO on trend strength, trading above more of its moving averages.
AHCO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.7 | $37.9 | +256% |
| 2021 | $37.9 | $23.7 | -37% |
| 2022 | $23.7 | $19.1 | -19% |
| 2023 | $19.1 | $7.29 | -62% |
| 2024 | $7.29 | $9.53 | +31% |
| 2025 | $9.53 | $10.3 | +7.6% |
| 2026 YTD | $10.3 | $7.87 | -23% |
AHCO's yearly returns have swung widely, from +256% in 2020 to −62% in 2023. It's down 23% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AHCO on returns for 2026, with the stronger performance.